Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It treats hypertension and is indicated for adults who require blood pressure control.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmetec Plus is an antihypertensive medication that acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure levels in patients with primary hypertension. - Hypertension with fluid retention: provides additional diuretic effect to reduce edema. - High‑risk cardiovascular patients: contributes to overall cardiovascular risk reduction when combined with lifestyle measures.

Olmetec Plus may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy with Olmetec Plus, consider the following precautions: - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially in patients on other diuretics. - Pregnancy: avoid use during pregnancy due to risk of fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Drug interactions: review concomitant medications for potential additive blood‑pressure effects. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olmetec Plus can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined use may cause excessive hypotension and renal impairment. - Lithium: risk of lithium toxicity may increase. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustment to avoid hypotension. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors: additive risk of angio‑edema and renal dysfunction.